Ingrezza is meant to minimise the amount of dopamine in a brain region that regulates movement and motor function. Credit: Raman Oza from Pixabay.

Neurocrine Biosciences has reported positive results from pooled analyses of the long-term effects of Ingrezza (valbenazine) in decreasing abnormal movements in tardive dyskinesia (TD) disorder.

TD is characterised by persistent involuntary movements of the face, torso and/or other body parts.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor intended to minimise the amount of dopamine in a brain region that regulates movement and motor function.

It has US Food and Drug Administration (FDA) approval to treat adults suffering from TD.

Pooled analyses from the Phase III KINECT 3 and KINECT 4 trials showed that a once-daily 40mg dose of the drug led to a response on the Abnormal Involuntary Movement Scale (AIMS) scale in 53.7% of patients treated for 48 weeks.

Ingrezza also demonstrated a Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) response in 65.5% of patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, data from the Phase III KINECT 3 trial revealed early response following two weeks of therapy with a 40mg or 80mg dose in 50% of participants.

Irrespective of the response at two weeks, meaningful reductions in the disorder were observed with long-term treatment.

According to the data, the drug was generally well-tolerated without any new safety concerns or notable worsening of psychiatric symptoms.

Neurocrine Biosciences chief medical officer Eiry Roberts said: “The analyses of pooled data continue to support the growing body of evidence that Ingrezza is an effective treatment for the long-term management of tardive dyskinesia.

“It is important to choose the best dosing option of Ingrezza and continue treatment to achieve long-term outcomes as tardive dyskinesia varies from patient to patient as well as their treatment response.”

The Phase III KINECT 3 and KINECT 4 studies were conducted in 234 and 163 moderate to severe TD patients, respectively.